Unicycive Therapeutics (UNCY) Competitors $0.52 +0.01 (+1.83%) (As of 10:26 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends UNCY vs. GNFT, STRO, TCRX, TRVI, AMRN, SOPH, INBX, ACRV, SLDB, and XBITShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Genfit (GNFT), Sutro Biopharma (STRO), TScan Therapeutics (TCRX), Trevi Therapeutics (TRVI), Amarin (AMRN), SOPHiA GENETICS (SOPH), Inhibrx (INBX), Acrivon Therapeutics (ACRV), Solid Biosciences (SLDB), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Genfit Sutro Biopharma TScan Therapeutics Trevi Therapeutics Amarin SOPHiA GENETICS Inhibrx Acrivon Therapeutics Solid Biosciences XBiotech Genfit (NASDAQ:GNFT) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk. Do analysts prefer GNFT or UNCY? Genfit currently has a consensus target price of $13.00, suggesting a potential upside of 201.62%. Unicycive Therapeutics has a consensus target price of $5.13, suggesting a potential upside of 888.05%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Genfit.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media prefer GNFT or UNCY? In the previous week, Unicycive Therapeutics had 12 more articles in the media than Genfit. MarketBeat recorded 15 mentions for Unicycive Therapeutics and 3 mentions for Genfit. Unicycive Therapeutics' average media sentiment score of 0.80 beat Genfit's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genfit 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Unicycive Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GNFT or UNCY more profitable? Company Net Margins Return on Equity Return on Assets GenfitN/A N/A N/A Unicycive Therapeutics N/A N/A -29.88% Which has more risk and volatility, GNFT or UNCY? Genfit has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Does the MarketBeat Community prefer GNFT or UNCY? Genfit received 39 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. However, 74.36% of users gave Unicycive Therapeutics an outperform vote while only 69.39% of users gave Genfit an outperform vote. CompanyUnderperformOutperformGenfitOutperform Votes6869.39% Underperform Votes3030.61% Unicycive TherapeuticsOutperform Votes2974.36% Underperform Votes1025.64% Which has stronger valuation & earnings, GNFT or UNCY? Unicycive Therapeutics has lower revenue, but higher earnings than Genfit. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenfit$41.31M5.21-$31.27MN/AN/AUnicycive Therapeutics$680K79.18-$30.54M-$0.97-0.53 Do institutionals & insiders believe in GNFT or UNCY? 2.2% of Genfit shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 4.2% of Genfit shares are held by company insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryUnicycive Therapeutics beats Genfit on 12 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.34M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-0.534.8389.0213.30Price / Sales77.76372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book1.897.876.085.74Net Income-$30.54M$153.61M$119.07M$225.93M7 Day Performance13.71%-2.00%-1.84%-1.32%1 Month Performance17.18%-7.47%-3.65%0.60%1 Year Performance1.47%31.80%31.62%26.23% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics3.4448 of 5 stars$0.52+1.8%$5.13+888.0%-2.0%$53.84M$680,000.00-0.539Analyst RevisionGap UpGNFTGenfit1.4608 of 5 stars$4.31+1.2%$13.00+201.6%+27.1%$215.28M$41.31M0.00120STROSutro Biopharma4.3663 of 5 stars$2.59-3.0%$12.14+368.8%-3.6%$213.57M$153.73M0.00240Analyst ForecastAnalyst RevisionTCRXTScan Therapeutics2.9905 of 5 stars$3.99-3.2%$12.00+200.8%-10.6%$211.35M$21.05M0.00100TRVITrevi Therapeutics3.4138 of 5 stars$2.73-1.4%$7.43+172.1%+113.1%$209.86MN/A-6.3020Gap UpAMRNAmarin0.1111 of 5 stars$0.50+2.1%N/A-37.4%$207.31M$306.91M0.00360SOPHSOPHiA GENETICS1.4237 of 5 stars$3.17flat$6.50+105.0%-14.6%$207.26M$62.37M0.00520INBXInhibrx1.8213 of 5 stars$14.11+0.5%N/A-36.9%$204.31M$1.63M0.00166ACRVAcrivon Therapeutics2.7362 of 5 stars$6.49-0.2%$23.67+264.7%+62.9%$202.10MN/A0.0058Analyst RevisionSLDBSolid Biosciences3.3235 of 5 stars$5.04+1.6%$15.14+200.5%+108.4%$201.40M$8.09M-1.63100Analyst RevisionXBITXBiotech0.8946 of 5 stars$6.60+1.7%N/A+77.8%$201.17M$4.01M-6.01100Positive News Related Companies and Tools Related Companies Genfit Alternatives Sutro Biopharma Alternatives TScan Therapeutics Alternatives Trevi Therapeutics Alternatives Amarin Alternatives SOPHiA GENETICS Alternatives Inhibrx Alternatives Acrivon Therapeutics Alternatives Solid Biosciences Alternatives XBiotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UNCY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
